MIG Fonds 18 has made its first investment in CoreMedic, aiming to advance a minimally invasive solution for mitral valve repair through the novel ChordArt technology.

Information on the Target

CoreMedic, the inaugural investment of MIG Fonds 18, specializes in innovative medical technology, specifically focused on the treatment of mitral valve insufficiency, a condition prevalent in older patients. This condition occurs when the mitral valve does not close properly, often due to the rupture of fine chordae tendineae that anchor the valve to the heart muscle. This complication can lead to heart failure, making intervention critical for affected patients.

The company's groundbreaking technology, known as ChordArt, offers a minimally invasive solution to replace the ruptured chordae tendineae via a catheter inserted through the femoral vein. This procedure allows for the replacement of these critical supports without the need for open-heart surgery, significantly reducing the risks associated with conventional surgical approaches. Patients previously treated with the ChordArt implant have shown stability over a five-year period, demonstrating the potential longevity and efficacy of this innovative solution.

Industry Overview in Germany

The medical technology sector in Germany is robust and continuously evolving, driven by advancements in health care and a strong focus on innovative solutions. With a well-established infrastructure supporting research and development,